2014
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse J, Schelling T, Sindelar J. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tobacco Control 2014, 24: 112. PMID: 25550419, PMCID: PMC4345832, DOI: 10.1136/tobaccocontrol-2014-052022.Peer-Reviewed Original ResearchConceptsEconomic impact analysisSound economic analysisNet economic benefitsImpact analysisProminent economistsSignificant regulatory actionsEconomic analysisDrug Administration's regulatory authorityNet benefitEconomic benefitsTobacco productsGraphic warning labelsRegulatory authoritiesLabel regulationsCostTobacco product regulationRegulatory actionProduct regulationEconomistsAuthoritiesBenefitsFuture analysesRulesControl ActJurisdictions
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence